Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 13, 2021 - Issue
Submit an article Journal homepage
179
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Mary Slavcev1 Global Market Access, Janssen Global Services, Raritan, NJ, USACorrespondence[email protected]
,
Allison Spinelli2 Global Medical Affairs, Janssen Global Services, Raritan, NJ, USA
,
Elisabeth Absalon3 Real World and Late Phase, Syneos Health Clinical SARL, Paris, France
,
Tara Masterson4 Medical Group Oncology, Janssen Research & Development, LLC, Spring House, PA, USAORCID Iconhttps://orcid.org/0000-0001-8061-3576
ORCID Icon,
Christoph Heuck4 Medical Group Oncology, Janssen Research & Development, LLC, Spring House, PA, USA
,
Annette Lam1 Global Market Access, Janssen Global Services, Raritan, NJ, USA
&
Erwin De Cock5 Real World and Late Phase, Syneos Health Clinical Spain SL, Madrid, Spain
 show all
Pages 465-473 | Published online: 08 Jun 2021

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ana Parra, Claudia Hernández & Laura Prieto-Pinto. (2023) Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-10.
Read now

Articles from other publishers (4)

Scott A. Soefje, Corinne Carpenter, Katherine Carlson, Samir Awasthi, Thomas S. Lin, Shuchita Kaila, Daniel Tarjan, Nikhil Kayal, Christian Kirkup, Tyler E. Wagner, Kathleen S. Gray & Shaji Kumar. (2023) Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers. JCO Oncology Practice 19:4, pages e542-e549.
Crossref
Ana Homšek, Jelena Spasić, Neda Nikolić, Tatjana Stanojković, Marija Jovanović, Branislava Miljković & Katarina M Vučićević. (2022) Pharmacokinetic characterization, benefits and barriers of subcutaneous administration of monoclonal antibodies in oncology. Journal of Oncology Pharmacy Practice 29:2, pages 431-440.
Crossref
Gordon Cook, John Ashcroft, Mariana Fernandez, Sarah Henshaw, Zeyad Khalaf, Guy Pratt, Anish Tailor & Neil Rabin. (2023) Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers. Frontiers in Oncology 13.
Crossref
Antonio Giovanni Solimando, Eleonora Malerba, Patrizia Leone, Marcella Prete, Carolina Terragna, Michele Cavo & Vito Racanelli. (2022) Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. Frontiers in Oncology 12.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.